UY38998A - Derivados de bencimidazol, su uso en medicina y composiciones que los contienen - Google Patents
Derivados de bencimidazol, su uso en medicina y composiciones que los contienenInfo
- Publication number
- UY38998A UY38998A UY0001038998A UY38998A UY38998A UY 38998 A UY38998 A UY 38998A UY 0001038998 A UY0001038998 A UY 0001038998A UY 38998 A UY38998 A UY 38998A UY 38998 A UY38998 A UY 38998A
- Authority
- UY
- Uruguay
- Prior art keywords
- medicine
- compositions containing
- benzimidazole derivatives
- benzimidazoles
- processes
- Prior art date
Links
- 150000001556 benzimidazoles Chemical class 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a bencimidazoles de la Fórmula (I) y sales de estos aceptables desde el punto de vista farmacéutico, en donde R1 a R6 son como se definen en la descripción; a su uso en la medicina; a composiciones que los contienen; a procesos para su preparación; y a intermediarios usados en dichos procesos. Los bencimidazoles de la Fórmula (I) son inhibidores de ITK y, por lo tanto, son potencialmente útiles en el tratamiento de diversos trastornos, que incluyen dermatitis atópica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962951030P | 2019-12-20 | 2019-12-20 | |
US202063108602P | 2020-11-02 | 2020-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38998A true UY38998A (es) | 2021-07-30 |
Family
ID=73856233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001038998A UY38998A (es) | 2019-12-20 | 2020-12-21 | Derivados de bencimidazol, su uso en medicina y composiciones que los contienen |
Country Status (19)
Country | Link |
---|---|
US (1) | US11661419B2 (es) |
EP (1) | EP4077316A1 (es) |
JP (1) | JP2023507138A (es) |
KR (1) | KR20220118525A (es) |
CN (1) | CN115087655A (es) |
AU (1) | AU2020405536B2 (es) |
BR (1) | BR112022011838A2 (es) |
CA (1) | CA3103120A1 (es) |
CL (1) | CL2022001675A1 (es) |
CO (1) | CO2022008313A2 (es) |
CR (1) | CR20220299A (es) |
DO (1) | DOP2022000130A (es) |
EC (1) | ECSP22049160A (es) |
IL (1) | IL293831B2 (es) |
MX (1) | MX2022007518A (es) |
PE (1) | PE20221916A1 (es) |
TW (1) | TWI766484B (es) |
UY (1) | UY38998A (es) |
WO (1) | WO2021124155A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4263526A1 (en) * | 2020-12-15 | 2023-10-25 | Pfizer Inc. | Benzimidazole derivatives and their use as inhibitors of itk for the treatment of skin disease |
CN114624358A (zh) * | 2022-03-11 | 2022-06-14 | 哈尔滨圣泰生物制药有限公司 | 一种地氯雷他定口服液的质量检测方法 |
WO2023249992A2 (en) * | 2022-06-21 | 2023-12-28 | Jjr&D, Llc | Topical benzimidazole formulations and methods for use in treating inflammatory dermatoses |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0901786B1 (en) | 1997-08-11 | 2007-06-13 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
MXPA04003954A (es) * | 2001-10-26 | 2004-11-29 | Aventis Pharma Inc | Bencimidazoles. |
FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
JP2003231687A (ja) | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | ピラゾリル縮合環化合物及びその医薬用途 |
WO2005105788A1 (en) | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
CN101160312A (zh) | 2005-04-14 | 2008-04-09 | 霍夫曼-拉罗奇有限公司 | 三环吡咯衍生物、它们的制备和作为药剂的应用 |
GB0602178D0 (en) | 2006-02-03 | 2006-03-15 | Merck Sharp & Dohme | Therapeutic treatment |
US20080070933A1 (en) | 2006-08-24 | 2008-03-20 | Huang Kenneth H | Purine, Pyrimidine, and Azaindole Derivatives |
ATE522536T1 (de) | 2008-02-25 | 2011-09-15 | Hoffmann La Roche | Pyrrolopyrazin-kinasehemmer |
CN101945877B (zh) | 2008-02-25 | 2013-07-03 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪激酶抑制剂 |
MX2010009023A (es) | 2008-02-25 | 2010-09-07 | Hoffmann La Roche | Inhibidores de cinasas de pirrolopirazina. |
CA2713710A1 (en) | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
ATE522534T1 (de) | 2008-02-25 | 2011-09-15 | Hoffmann La Roche | Pyrrolopyrazin-kinasehemmer |
EP2196458A1 (en) | 2008-12-10 | 2010-06-16 | Laboratorios Del. Dr. Esteve, S.A. | Process for obtaining enantiomerically enriched pyrazole derivatives |
EP2202232A1 (en) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
EP2292237A1 (en) | 2009-08-14 | 2011-03-09 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention or treatment of pain induced by chemotherapy |
US8299070B2 (en) | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
EP2366702A1 (en) | 2010-03-18 | 2011-09-21 | Almirall, S.A. | New oxadiazole derivatives |
US8481541B2 (en) | 2010-03-22 | 2013-07-09 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
CN102906095A (zh) | 2010-05-20 | 2013-01-30 | 弗·哈夫曼-拉罗切有限公司 | 作为syk和jak抑制剂的吡咯并吡嗪衍生物 |
TR201821217T4 (tr) * | 2010-06-23 | 2019-01-21 | Hanmi Science Co Ltd | Tirozin kinaz aktivitesinin inhibisyonu için yeni kaynaşmış pirimidin türevleri. |
EP2615916B1 (en) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
EP2455081A1 (en) | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of crohn's disease |
EP2455080A1 (en) | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
MA34948B1 (fr) | 2011-02-07 | 2014-03-01 | Plexxikon Inc | Composes et procedes de modulation de kinase, et leurs indications |
MX2014001595A (es) | 2011-08-12 | 2014-04-14 | Hoffmann La Roche | Compuestos de imidazol, composiciones y metodos de uso. |
JP6096778B2 (ja) | 2011-09-01 | 2017-03-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ピロロピラジンキナーゼ阻害剤 |
JP2015528435A (ja) | 2012-08-10 | 2015-09-28 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ピラゾールカルボキサミド化合物、組成物及び使用方法 |
WO2014041518A1 (en) | 2012-09-14 | 2014-03-20 | Glenmark Pharmaceuticals S.A. | Thienopyrrole derivatives as itk inhibitors |
DK2900657T3 (da) | 2012-09-26 | 2020-05-04 | Hoffmann La Roche | Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse |
CN103804364A (zh) | 2012-11-06 | 2014-05-21 | 韩冰 | 一类治疗缺血性脑损伤的化合物及其用途 |
CN103800328A (zh) | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
CN103800337A (zh) | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
CN103804291A (zh) | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
CN103804361A (zh) | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
CN103800340A (zh) | 2012-11-09 | 2014-05-21 | 韩冰 | 一类治疗青光眼的化合物及其用途 |
CN103800327A (zh) | 2012-11-09 | 2014-05-21 | 韩冰 | 一类治疗青光眼的化合物及其用途 |
CN103804302A (zh) | 2012-11-14 | 2014-05-21 | 杨育新 | 一类治疗创伤性脑损伤疾病的化合物及其用途 |
CN103804351A (zh) | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
CN103804363A (zh) | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
CN103804272A (zh) | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
CN104628657A (zh) | 2013-11-06 | 2015-05-20 | 韩冰 | 一类治疗缺血性脑损伤的化合物及其用途 |
WO2016001341A1 (en) | 2014-07-03 | 2016-01-07 | F. Hoffmann-La Roche Ag | Sulfonylaminopyridine compounds, compositions and methods of use |
CN110845482B (zh) | 2014-07-04 | 2024-01-19 | 日本烟草产业株式会社 | 制备吲哚化合物的方法 |
WO2016010108A1 (ja) | 2014-07-18 | 2016-01-21 | 塩野義製薬株式会社 | 含窒素複素環誘導体およびそれらを含有する医薬組成物 |
CN105524067A (zh) | 2014-09-28 | 2016-04-27 | 江苏柯菲平医药股份有限公司 | 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 |
WO2016091916A1 (en) | 2014-12-10 | 2016-06-16 | F. Hoffmann-La Roche Ag | Pyrazolylaminopurines as itk inhibitors |
WO2016115455A2 (en) | 2015-01-15 | 2016-07-21 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | 6-aryl-7-substituted-3-(1h-pyrazol-5-yl)-7h-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the stat3 pathway with anti-proliferative activity |
AU2016287581B2 (en) | 2015-07-02 | 2019-06-06 | F. Hoffmann-La Roche Ag | Bicyclic lactams and methods of use thereof |
MX2020012644A (es) | 2018-05-25 | 2021-01-29 | Japan Tobacco Inc | Metodo para tratar dolor o cistitis intersticial utilizando compuesto de indol. |
US12011448B2 (en) | 2018-05-25 | 2024-06-18 | Japan Tobacco Inc. | Therapeutic or preventing agent for nephrotic syndrome including indole compound |
US20210236503A1 (en) | 2018-05-25 | 2021-08-05 | Japan Tobacco Inc. | Therapeutic or preventing agent for multiple sclerosis including indole compound |
EP4263526A1 (en) * | 2020-12-15 | 2023-10-25 | Pfizer Inc. | Benzimidazole derivatives and their use as inhibitors of itk for the treatment of skin disease |
-
2020
- 2020-12-16 CN CN202080096751.1A patent/CN115087655A/zh active Pending
- 2020-12-16 EP EP20828341.6A patent/EP4077316A1/en active Pending
- 2020-12-16 JP JP2022537036A patent/JP2023507138A/ja active Pending
- 2020-12-16 PE PE2022001143A patent/PE20221916A1/es unknown
- 2020-12-16 MX MX2022007518A patent/MX2022007518A/es unknown
- 2020-12-16 IL IL293831A patent/IL293831B2/en unknown
- 2020-12-16 CR CR20220299A patent/CR20220299A/es unknown
- 2020-12-16 WO PCT/IB2020/062036 patent/WO2021124155A1/en active Application Filing
- 2020-12-16 KR KR1020227025150A patent/KR20220118525A/ko not_active Application Discontinuation
- 2020-12-16 AU AU2020405536A patent/AU2020405536B2/en active Active
- 2020-12-16 BR BR112022011838A patent/BR112022011838A2/pt not_active Application Discontinuation
- 2020-12-17 CA CA3103120A patent/CA3103120A1/en active Pending
- 2020-12-18 US US17/126,358 patent/US11661419B2/en active Active
- 2020-12-18 TW TW109144868A patent/TWI766484B/zh active
- 2020-12-21 UY UY0001038998A patent/UY38998A/es unknown
-
2022
- 2022-06-14 CO CONC2022/0008313A patent/CO2022008313A2/es unknown
- 2022-06-17 DO DO2022000130A patent/DOP2022000130A/es unknown
- 2022-06-17 CL CL2022001675A patent/CL2022001675A1/es unknown
- 2022-06-20 EC ECSENADI202249160A patent/ECSP22049160A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CR20220299A (es) | 2022-08-05 |
DOP2022000130A (es) | 2022-07-31 |
CL2022001675A1 (es) | 2023-03-17 |
JP2023507138A (ja) | 2023-02-21 |
WO2021124155A1 (en) | 2021-06-24 |
IL293831B1 (en) | 2023-10-01 |
EP4077316A1 (en) | 2022-10-26 |
TWI766484B (zh) | 2022-06-01 |
CA3103120A1 (en) | 2021-06-20 |
CO2022008313A2 (es) | 2022-07-08 |
AU2020405536B2 (en) | 2023-09-07 |
BR112022011838A2 (pt) | 2022-08-30 |
IL293831A (en) | 2022-08-01 |
ECSP22049160A (es) | 2022-07-29 |
PE20221916A1 (es) | 2022-12-23 |
IL293831B2 (en) | 2024-02-01 |
AU2020405536A1 (en) | 2022-07-14 |
US11661419B2 (en) | 2023-05-30 |
KR20220118525A (ko) | 2022-08-25 |
MX2022007518A (es) | 2022-09-19 |
CN115087655A (zh) | 2022-09-20 |
TW202130634A (zh) | 2021-08-16 |
US20210188829A1 (en) | 2021-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019001077A1 (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer. | |
ECSP20070854A (es) | Compuestos heteroaril tetracíclicos | |
UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
UY38998A (es) | Derivados de bencimidazol, su uso en medicina y composiciones que los contienen | |
UY38076A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
CO2017009891A2 (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta) | |
CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
UY36244A (es) | Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen | |
SV2016005171A (es) | Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih | |
NI201500048A (es) | Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih | |
UY36649A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
CL2021001190A1 (es) | Compuestos de azalactam como inhibidores de hpk1 | |
ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
UY35535A (es) | ?Derivados de fenil sulfonamidas?. | |
UY36003A (es) | Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina. | |
UY35275A (es) | Derivados de aminopirazina | |
CL2019001991A1 (es) | Moduladores del receptor de estrógeno. | |
CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
CR20160084A (es) | Derivados de amida como agonistas del receptor del ácido lisofosfatídico | |
CR20180091A (es) | 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del vih | |
UY35536A (es) | ?derivados de sulfonamida?. | |
ECSP21037191A (es) | Pirazoles como moduladores de la hemoglobina | |
CO2021001925A2 (es) | Piridopirimidinas como inhibidores del receptor de histamina h4 | |
ECSP18056196A (es) | Derivados de indano | |
DOP2022000203A (es) | 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad antagonista gpr52 |